<p>Due to the paucity of patient derived models in rare cancers, identification of therapeutic targets remains challenging. We developed a patient derived model, CLF-PED-015-T, from a patient with an undifferentiated sarcoma. From this model, we performed pooled RNAi and CRISPR-Cas9 negative selection screens and integrated that with a small molecule screen. Integration of these data identified CDK4 and XPO1 as potential therapeutic targets.</p>

Integrated Genetic and Pharmacologic Interrogation of Rare Cancers

Sarcoma study with RNA-Seq, SNV Aggregate (.MAF) + 1 more data on dbGaP (1 participants)